<DOC>
	<DOCNO>NCT01354691</DOCNO>
	<brief_summary>For many , Alzheimer 's disease number one medical issue face age society . It late onset neurodegenerative disease , frequently diagnose , impairs memory cognitive performance . There know treatment either prevent reverse progression . Consequently , still remain need evaluate treatment well stabilize symptoms disease . These symptom frequently include decreased functional capacity negative psychological attribute ( e , g , depression , anxiety ) association memory cognition deficit . This current study do assess investigational compound design improved cognitive status affect patient also well manage symptom . Hence , ultimate goal provide patient improve quality life slow progression neurodegenerative disease</brief_summary>
	<brief_title>Safety Efficacy Study Ladostigil Mild Moderate Probable Alzheimer 's Disease</brief_title>
	<detailed_description>This phase II , proof concept study evaluate safety efficacy investigational compound ladostigil versus placebo mild moderate Alzheimer 's disease patient . The randomized , double-blind , placebo-controlled phase trial 26 week duration involve two cohort ( i.e . one arm receiving ladostigil one arm receiving placebo ) . After initial 26 week period , participate subject receive 26 week treatment ladostigil ( i.e . open label phase ) . A total five territory participate trial . These include Austria , Croatia , Germany , Serbia Spain .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Memory Disorders</mesh_term>
	<mesh_term>Amnesia</mesh_term>
	<criteria>AD diagnosis accord NINCDSADRDA criterion Mild moderate AD accord MMSE 1424 inclusive MRI CT assessment within 6 month baseline , corroborate clinical diagnosis exclude potential cause dementia especially cerebrovascular lesion Absence major depressive disease accord CSDD le equal 18 Modified Hachinski Ischemic Scale equal 4 Education eight year Previous decline cognition six month document patient medical record A caregiver available living household interact patient daily available necessary assure administration investigational product Patients living home nursing home set without continuous nursing care General health status acceptable participation 12month clinical trial ability swallow oral medication No history treatment rivastigmine For patient either donepezil galantamine anticholinesterase inhibitor treatment prescribe , stop treatment four week prior screen For patient memantine treatment prescribe , stop treatment four week prior screen Other primary degenerative dementia ( e.g . dementia Lewy body , frontotemporal dementia , Huntington 's disease , JacobCreutzfeldt disease ) Other neurodegenerative condition ( Parkinson 's disease . amyotrophic lateral sclerosis , etc ) Other central nervous system disease ( severe head trauma , tumor , subdural hematoma , etc ) A current DSMIV diagnosis active major depression , schizophrenia bipolar disorder Seizure disorder Other infectious , metabolic systemic disease affect central nervous system ( syphilis , present hypothyroidism , present vitamin B12 folate deficiency , serum electrolyte normal range , juvenile onset diabetes mellitus , etc ) Clinically significant , advanced unstable disease may interfere primary secondary variable evaluation Other unstable , chronic clinically significant medical condition involve major organ like kidney , liver , lung heart/vasculature Hospitalization change chronic concomitant medication one month prior screen screen period</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Memory Loss</keyword>
	<keyword>Cognitive Impairment</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Delirium , Dementia , Amnestic , Cognitive Disorders</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Depression</keyword>
	<keyword>Anxiety</keyword>
</DOC>